Novavax, Inc. (NVAX) News
Filter NVAX News Items
NVAX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NVAX News Highlights
- For NVAX, its 30 day story count is now at 15.
- Over the past 22 days, the trend for NVAX's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
- The most mentioned tickers in articles about NVAX are SHOT, AIM and BEAT.
Latest NVAX News From Around the Web
Below are the latest news stories about NOVAVAX INC that investors may wish to consider to help them evaluate NVAX as an investment opportunity.
Is Novavax Stock a Buy Now?Biotech company Novavax (NASDAQ: NVAX) went from being relatively unknown just four years ago to becoming one of the U.S. COVID-19 vaccine market leaders. The company has faced many trials and tribulations in this period, however. If Novavax can mount a comeback, now may be as good a time as any to press the buy button while its shares are changing hands for just about $5.46 apiece. |
3 Short-Squeeze Stocks That Could Take Off Before Year-EndThese three short-squeeze stocks are seeing high short interest. |
‘Nobody wants to speak about COVID’: Less than 3% of eligible Americans got a booster shot in September — does that mean trouble for these 3 big vaccine stocks?Market performance hangs on U.S. vaccination rates for these three companies. |
Novavax's (NVAX) Updated COVID Jab Gets WHO Nod for Emergency UseFollowing this authorization, Novavax's (NVAX) updated COVID-19 vaccine is available as an option to all 194 WHO member states. |
Is Novavax Stock A Buy After WHO Signs Off On Its Updated Covid Booster?Novavax stock is on the rise after the World Health Organization signed off on its Covid shot. Is NVAX stock a buy or a sell right now? |
UPDATE 2-WHO authorizes emergency use of Novavax's updated COVID shotNovavax's updated vaccine has been granted emergency-use authorization by the World Health Organization (WHO) for active immunization to prevent COVID-19 in individuals aged 12 and older, the company said on Tuesday. The updated Novavax shot, which was authorized in the U.S. last month, targets a descendant of the XBB lineage of the coronavirus that was globally predominant earlier this year. The emergency use listing helps speed up the regulatory approvals to import and administer the vaccines by member states, according to the WHO. |
Novavax's Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health OrganizationNovavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Nuvaxovid™ XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) has been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunization to prevent COVID-19 in individuals aged 12 and older. The EUL assists WHO member states in assessing vaccines with the aim of expediting availability and enables the WHO's 194 member states to expedite regulatory |
Novavax Makes Changes to Executive Leadership Team to Enhance Focus on Delivery of Strategic PrioritiesNovavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced changes to its executive leadership team designed to enhance focus on its strategic priorities and continue the evolution of the Company's scale and structure announced last week. |
Could a Short Squeeze Be Coming for These 3 Heavily Shorted Stocks?Wall Street traders have numerous (and often creative) strategies to speculate on stocks and their up and down price movements. There are times when the prices of stocks are influenced more by what these traders do rather than by the company's business operations. One popular strategy favored by the market bears involves selling a stock "short." |
Where Will Novavax Be in 3 Years?A lot can happen in just a few years, and Novavax (NASDAQ: NVAX) is the proof of that. Three years ago, the company was rushing toward the coronavirus vaccine finish line -- and the shares were soaring. Novavax brought its vaccine to market, but its late arrival meant it lost out on the biggest revenue opportunity. |